Effective at the market close on Wednesday, October 19, CCXIwill be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights.
On August 4, 2022, ChemoCentryx, Inc. agreed to be acquired by Amgen for $52.00 per share in cash.
